 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Acorda Therapeutics, Inc. (ACOR) is a biopharmaceutical company.
The firm identifies, develops, and commercializes novel therapies for multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system in the United States.
The companys products include Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with MS; Zanaflex Capsules and Zanaflex tablets, a short-acting drug for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain.
It is also involved in developing Diazapam Nasal Spray for the treatment of cluster/acute repetitive seizures; Dalfampridine that is in Phase III clinical development program preparations for post-stroke deficits; NP-1998, a topical solution that is in phase III clinical trail for the treatment of neuropathic pain; AC105, which is in Phase II clinical trials for the treatment of SCI; Neuregulin Program that has completed Phase 1 clinical trial for the treatment of heart failure; Remyelinating Antibodies Program, which is in Phase 1 clinical trial for the treatment of MS; and Chondroitinase Program that is in research for the treatment of injuries to the brain and spinal cord, as well as other neurotraumatic indications.
Shares are heading higher in an upward trading channel. We expect shares to see a modest pull back to the lower boundary of the channel. Use any pullback to establish a new position! The firm report its quarterly results in the second week of February!
52-Week Trading Range: $28.26 to $45.45
Entry Point: $42.10
Stop Loss: $39.95
Targer Price: $46.52
ACOR fell below our stop loss. Closed at $39.60
